0000000000512755

AUTHOR

Mariana Nepomuceno

0000-0003-4231-9215

showing 2 related works from this author

Is Sleep Disruption a Cause or Consequence of Alzheimer’s Disease? Reviewing Its Possible Role as a Biomarker

2020

In recent years, the idea that sleep is critical for cognitive processing has gained strength. Alzheimer’s disease (AD) is the most common form of dementia worldwide and presents a high prevalence of sleep disturbances. However, it is difficult to establish causal relations, since a vicious circle emerges between different aspects of the disease. Nowadays, we know that sleep is crucial to consolidate memory and to remove the excess of beta-amyloid and hyperphosphorilated tau accumulated in AD patients’ brains. In this review, we discuss how sleep disturbances often precede in years some pathological traits, as well as cognitive decline, in AD. We describe the relevance of sleep to memory co…

Sleep Wake Disorders0301 basic medicineswstau ProteinsReviewDiseaseNon-rapid eye movement sleepCatalysiscsf taulcsh:ChemistryInorganic Chemistry03 medical and health sciencesCognition0302 clinical medicineAlzheimer DiseaseMemoryremmedicineHumansDementiaPhysical and Theoretical ChemistryCognitive declinelcsh:QH301-705.5Molecular BiologySpectroscopyAmyloid beta-Peptidesbusiness.industryOrganic ChemistryCognitionGeneral Medicinemedicine.diseaseSleep in non-human animalsComputer Science Applicationsnremswa030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Biomarker (medicine)Memory consolidationbusinessspindlesNeuroscienceBiomarkers030217 neurology & neurosurgerycsf amyloidInternational Journal of Molecular Sciences
researchProduct

When Does Alzheimer′s Disease Really Start? The Role of Biomarkers

2021

While Alzheimer’s disease (AD) classical diagnostic criteria rely on clinical data from a stablished symptomatic disease, newer criteria aim to identify the disease in its earlier stages. For that, they incorporated the use of AD’s specific biomarkers to reach a diagnosis, including the identification of Aβ and tau depositions, glucose hypometabolism, and cerebral atrophy. These biomarkers created a new concept of the disease, in which AD’s main pathological processes have already taken place decades before we can clinically diagnose the first symptoms. Therefore, AD is now considered a dynamic disease with a gradual progression, and dementia is its final stage. With …

0301 basic medicinemedicine.medical_specialtyad spectrumGradual progressionVariable timeInfluential PublicationsReviewDiseaseCatalysislcsh:ChemistryInorganic Chemistry03 medical and health sciences0302 clinical medicineAlzheimer DiseaseRisk FactorsmedicineHumansDementiaPhysical and Theoretical ChemistryIntensive care medicineCognitive impairmentlcsh:QH301-705.5Molecular BiologyPathologicalad dynamicimaging biomarkersSpectroscopyCerebral atrophybusiness.industryOrganic ChemistrybiomarkerscsfGeneral Medicinemedicine.diseaseComputer Science Applications030104 developmental biologylcsh:Biology (General)lcsh:QD1-999business030217 neurology & neurosurgerydementiaInternational Journal of Molecular Sciences
researchProduct